Tag: the war on (some) drugs

Louisiana Governor Vetoes Bill That Would Have Let Him Pardon Past Marijuana Convictions

The governor of Louisiana has vetoed a bill that would have allowed him and future governors to issue pardons for people with past marijuana convictions.

Gov. Jeff Landry (R) rejected the legislation on Wednesday, about a month after it was approved in the legislature. It remains to be seen what he will do with separate proposals to decriminalize cannabis paraphernalia and regulate hemp products that have also been sent to his desk.

The pardon bill from Rep. Delisha Boyd (D) would have made people convicted of cannabis possession eligible for a gubernatorial pardon after paying all court costs associated with the offense, without the need for a recommendation from the Board of Pardons.

Individuals could have only received a pardon for their first possession offense, and anyone “who received such pardon shall not be entitled to receive another pardon by the governor pursuant to this Section,” the legislation says.

Kevin Caldwell, Southeast legislative manager for the advocacy group Marijuana Policy Project (MPP), said his organization is “saddened” by the governor’s veto of the bill.

“This legislation would have granted him the authority to pardon tens of thousands Louisianans who have a cannabis conviction on their records,” he told Marijuana Moment in an email. “This is a missed opportunity to help everyday citizens better their lives and economic opportunities.”

“This legislation was always about improving opportunities,” Caldwell added. “The strong bipartisan support this legislation achieved is a testament to the level of support sensible cannabis policy has in Louisiana.”

Meanwhile, the governor still has several other cannabis bills pending action.

Keep reading

Arizona Governor Signs Bill To Allow Workers’ Compensation For MDMA Treatment, Despite Vetoing Psilocybin Proposal

The governor of Arizona has signed a bill into law that would allow firefighters and peace officers with post-traumatic stress disorder (PTSD) to get workers’ compensation coverage for MDMA therapy if it is federally legalized.

While Gov. Katie Hobbs (D) vetoed a separate proposal to legalize psilocybin service centers this week, she gave final approval on Tuesday to legislation that would authorize the Industrial Commission of Arizona to provide public safety officials who have PTSD with compensation for a one-course treatment of MDMA if the drug is approved by the federal Food and Drug Administration (FDA).

The measure is being enacted weeks after an FDA advisory committee recommended against approving a new drug application for MDMA-assisted therapy, drawing criticism from advocates and certain lawmakers, including a GOP congressman who personally benefitted from psychedelic treatment.

The Arizona bill from Sen. David Gowan (R) is fairly limited in its scope, especially compared to the psychedelics services legislation the governor vetoed this week. Not only would it require FDA approval of MDMA, but it also doesn’t create a framework for therapeutic administration. It simply allows officials to approve workers compensation for a course of MDMA-assisted treatment sessions.

“If an independent medical examination reveals a treatment protocol of midomafetamine is deemed a reasonable and necessary treatment and follows the treatment guidelines established by the Industrial Commission of Arizona, workers’ compensation coverage may include on complete course of a treatment protocol of midomafetamine as prescribed by a psychiatrist,” the bill text says.

The commission would also be required to submit a report about the costs of the MDMA treatment to the Joint Legislative Budget Committee each year starting on or before January 1, 2026.

Keep reading

If Opiates Are Killing Americans, Why Won’t the FDA Let Us Try an Alternative?

For more than a decade, patients who’ve needed certain controlled medications have suffered from ill-advised, untenable policies the U.S. government has instituted, allegedly to mitigate the ever-surging numbers of drug overdose deaths. These policies have been a dismal failure on multiple fronts: Not only have deaths continued to surge, but the terrifying intrusion of the Drug Enforcement Administration (DEA) into the practice of medicine has had a chilling effect on patients and their physicians. 

As the DEA relentlessly tightens production quotas on medications for pain and ADHD, it has begun tracking every pill, making doctors increasingly reluctant to prescribe any controlled drugs and leaving many patients in a lurch. Perhaps worse, DEA production quotas have caused the back-order of multiple drugs—an increasingly common burden for patients, even those fortunate to have doctors willing to risk a DEA drug bust for simply doing their job.

The ill and disabled suffer the most. Virtually all patients who have diseases or chronic pain conditions will say that the emergency department is the single worst place to go for relief from severe pain. Doctors and hospitals are often more concerned about law enforcement looking over their shoulders than patient care. Patients desperate for pain relief often turn to street drugs, where they fall victim to counterfeit pills that contain fentanyl (or worse) instead of a legal opioid. 

By contrast, doctors in Australia, Canada, the United Kingdom, and throughout Europe have been using a fixed-dose, inhaled general anesthesia medicine that effectively reduces acute pain—a medication denied to Americans by a seemingly indifferent Food and Drug Administration (FDA). 

Doctors commonly used methoxyflurane (Penthrane) as a general anesthetic in the 1960s and 1970s. But, because it had toxic effects on the liver and kidneys, anesthesiologists gradually stopped using it and turned to safer anesthetics. In 2005, the FDA removed methoxyflurane from the market.

However, an Australian company, Medical Developments International, has been marketing a lower-dose, self-administered, single-use nasal inhaler version of methoxyflurane for 30 years. Its brand name is Penthrox, though many people refer to it as the “green whistle,” because of the package it comes in. People living in Europe have had access to the green whistle since 2015, and Canadian patients have had it since 2018. 

In 2020, a randomized controlled clinical trial in the U.K. demonstrated that the drug saved an average of 71 minutes in providing pain relief to accident and emergency department patients. Likewise, a 2020 Australian trial found that a methoxyflurane inhaler “was associated with clinically significant lower pain scores compared to standard therapy.” While it may cause drowsiness in some people, methoxyflurane at this low dose has few adverse effects, such as liver and kidney toxicity, and there are no reported cases of addiction or abuse. 

In 2022, the FDA finally lifted its “clinical hold” on methoxyflurane nasal inhalers and has allowed its manufacturer to resume FDA-supervised clinical trials. Unfortunately, this is an unnecessary waste of time.

Keep reading

Older Patients Using Medical Cannabis ‘Experience Considerable Improvement In Health And Well-Being,’ Study Finds

A new study on the impacts of medical marijuana on older adults finds that cannabis-based products may provide multiple therapeutic benefits for the demographic, including for health, well-being, sleep and mood.

Authors also observed “sizable reductions in pain severity and pain interference among older aged patients [reporting] chronic pain as their primary condition.”

The research, published this week in the journal Drugs and Aging, is meant to address what authors call “a general paucity of high quality research” around cannabis and older adults “and a common methodological practice of excluding those aged over 65 years from clinical trials” at a time when older patients are increasingly turning to medical marijuana for relief.

“International evidence that older individuals may be the fastest-growing increase in the use of medical marijuana, coupled with their frequent exclusion from controlled trials, indicates a growing need for real-world evidence to assess the effectiveness and safety of these drugs for older individuals,” the paper says.

Keep reading

Arizona’s Democratic Governor Vetoes Bill To Legalize Psilocybin Service Centers

The Democratic governor of Arizona has vetoed a bill to legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.

Less than a week after lawmakers gave final approval to the legislation, Gov. Katie Hobbs (D) rejected it on Tuesday, arguing that while the psychedelic may hold therapeutic potential, “we do not yet have the evidence needed to support widespread clinical expansion.”

“Arizonans with depression and PTSD deserve access to treatments that may be seen as outside the mainstream, but they should not be the subject of experiments for unproven therapies with a lack of appropriate guardrails,” the governor said in a veto message.

She also said that the bill’s estimated cost is $400,000 per year, which wasn’t accounted for in the budget.

Under the now-vetoed legislation, the Department of Human Services (DHS) would have been authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could have administered the psychedelic.

The measure would have significantly expanded on Arizona’s existing research-focused psychedelics law that provides $5 million in annual funding to support studies into psilocybin therapy.

Hobbs cited that research funding in her statement, saying the goal is to “ensure that those who seek psilocybin treatment are doing so confidently and safely under proper supervision of qualified professionals with documented and verified research to support the treatment.”

She said that money “will be allowed to continue with this year’s budget,” with a separate funding bill she signed into law on Tuesday protecting those dollars, which are exempt from lapsing appropriations provisions.

The vetoed proposal, meanwhile, would have established an Arizona Psilocybin Advisory Board, comprised of members appointed by the governor and legislative leaders. Representatives of the attorney general’s office and DHS, as well as military veterans, first responders, scientists with experience with psilocybin and physicians would have been among the members.

The board would have been responsible for establishing training criteria for psilocybin service center staff, making recommendations on the implementation of the law, and studying the science and policy developments related to psychedelics.

Sen. T. J. Shope (R), the bill’s sponsor, told The Center Square that the veto is a “disappointing result after months of hard work and the overwhelming bipartisan support this received in both houses of the Legislature this year.”

The senator added that if lawmakers were still in session, he’d be pushing for a vote to override the veto, but he’ll have to “settle for trying again next year.”

Keep reading

Portland Baseball Team Becomes First Sports Team to Legally Sell THC Products During Games

The Portland Pickles baseball organization will become the first sports team in the United States to sell marijuana-based products during a live sporting event legally.

In an announcement, the Pickles revealed they have a new partnership with Cycling Frog, which sells THC-based seltzer drinks.

The team will start selling the THC-based seltzer drinks at their stadium on June 18th.

According to Oregon Live, the Seltzer drink contains 2MG of THC and 4MG of CBG and is available in lemon and passion fruit flavors.

Ross Campbell, the Pickles’ VP of Business Development, said, “The Portland Pickles have a responsibility in the sports industry to take leaps and set a precedent of innovative partnerships.”

Fans who want to purchase the drink must be over 21.

Keep reading

Congressman Seeks To Block Feds From Seizing Marijuana From State-Legal Businesses Amid New Mexico Border Patrol Controversy

U.S. border patrol agents would be prevented from using its funds to seize marijuana from state-licensed businesses under a newly filed amendment to a large-scale spending bill.

Rep. Gabe Vasquez (D-NM) submitted the amendment for consideration as part of 2025 Fiscal Year appropriations legislation covering the Department of Homeland Security (DHS).

The move appears to be responsive to recent reporting about Customs and Border Protection (CBP) agents seizing hundreds of thousands of dollars worth of cannabis from state-legal businesses in New Mexico over recent months.

The amendment, which would need to be made in order for floor consideration by the House Rules Committee, reads:

SEC_. None of the funds made available by this Act may be used to seize cannabis or products containing cannabis that are possessed, sold, or transferred by a cannabis distributor, licensed by a State, or a business in a State where cannabis has been legalized for recreational or medicinal use.

This is the latest in a series of drug policy-related amendments to be filed from lawmakers across the aisle that they’ve sought to attach to spending bills. Rep. Robert Garcia (D-CA) has also filed an amendment to the DHS measure—as well as to separate appropriations legislation covering State, Foreign Operations, and Related Programs—that would prevent the relevant agencies from testing job applicants for cannabis in states where it’s legal.

While Garcia has repeatedly attempted to enact that reform as part of numerous legislative packages, this is the first time that the language of the Vasquez amendment has been introduced.

The Rules committee is expected to meet next week to decide which amendments to the bills can receive floor votes.

The controversy over CBP seizures of marijuana from state-licensed businesses has prompted responses from multiple levels of government.

Keep reading

Big Pharma’s supply chain is CRUMBLING as drug shortages reach decade high

The United States Pharmacopeia, an independent, science-based nonprofit, released its first annual Drug Shortage Report (USP) showing that drug shortages are currently at the highest level in a decade with 2023 marking the worst year yet.

Over the past 10 years, the number of drug shortages has increased dramatically, the report explains, with 125 active drug shortages monitored by the U.S. Food and Drug Administration (FDA) at the end of 2023.

“This high number of shortages is a direct result of persistent market vulnerabilities,” the report states. “According to our analysis, over a quarter of drugs in shortage were new drug shortages (34 products) in 2023.”

Published in early June, the report explains that the average drug shortage lasts more than three years and impacts multiple types of drugs. One in four drug shortages lasted more than five years while six drugs, including epinephrine injections for serious allergic reactions, has been in low supply for a decade. More than half of all new drug shortages involve injectable generic medications.

“Unexpected shocks can break the system and disrupt the supply of quality medicines,” said Anthony Lakavage, senior vice president for Global External Affairs at USP, a nonprofit organization that sets global quality standards for medications, dietary supplements and food ingredients.

“This worrisome trajectory leads to more frequent drug shortages, prolonged scarcity, and more people at risk of not getting the medicines they need, when they need them.”

(Related: Pharmaceutical drug manufacturing has degraded so badly with so many contamination problems that the Department of Defense [DoD] has intervened to call for outside testing.)

Keep reading

Gov-funded Maine non-profit gives kits to addicts to allow them to take drugs anally

A taxpayer-funded nonprofit in Maine, Maine Access Points (MAP), along with the city of Portland’s needle distribution center, is offering how-to guides and kits for “boofing,” a method where drug users squirt drugs up their rectum.

According to a report by the Maine Wire, Portland, Maine is providing drug users with a “Portland Public Health Boofing Kit” which includes a needleless syringe and an informational flyer explaining the technique for boofing. The method can be used for drugs such as heroin, fentanyl, and meth. 

The instructions advise users to find a safe spot, mix the drugs with saline in a provided tin, clean their hands and rectum, and use the provided lubricant to ease the syringe’s insertion. It also recommended those interested in using this method to empty their bowels beforehand.

The flyer instructs users to lay on their side in a fetal position or any comfortable position, insert the syringe tip into the rectum, release the mixture, and keep the syringe in place for a minute to prevent leakage. 

“Stay on your side laying down for a few minutes to let [the drugs] absorb in the membrane,” the guide said. “Then… You’re good to go!”

This method is recommended for users who experience issues with other forms of drug consumption, such as lung problems from smoking. The flyer also notes that this method may cause drugs to hit “harder or faster” compared to smoking or sniffing.

Keep reading

New York Senators Call For Investigation Of State’s Marijuana Social Equity Fund After Exposé Of ‘Predatory Deals’

Citing an investigation by THE CITY, two state senators have called for New York’s social equity cannabis fund to cease issuing loans to dispensary operators and for any “trapped in these predatory deals to be made whole.”

“What this story describes is not a social equity fund. We must get to the bottom of this,” State Sens. Liz Krueger (D-Manhattan) and Gustavo Rivera (D-The Bronx) asserted in a joint statement that pointed to the high interest rates and start-up costs highlighted in the article.

They called for an investigation by the state’s inspector general of the public–private fund, which was designed to finance a form of reparation for people whose lives had been disrupted by decades of racially discriminatory drug laws.

The governor’s office did not immediately respond to a request for comment. The office has repeatedly refused to answer detailed questions from THE CITY seeking greater clarity about the fund’s operations.

THE CITY’s investigation found that officials of the state’s Office of Cannabis Management, or OCM, had repeatedly warned the governor’s office for months about how the cannabis investment fund was being managed. They raised red flags about how dispensary operators were being loaded with steep costs and trapped in loans with strict terms that they believed were likely to lead to defaults. And OCM’s own counsel warned in an email that the licensees would likely default on their loans under the proposed terms.

The story was based on more than 500 internal agency emails, memos and presentations from July 2022 to July 2023 when the state was having trouble opening more than just a handful of dispensaries.

Calling the fund’s practices “unscrupulous,” the legislators said, “We must take action to redress these loan agreements.”

Keep reading